Cravens & Co Advisors LLC Acquires 71 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cravens & Co Advisors LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,305 shares of the biopharmaceutical company’s stock after purchasing an additional 71 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.1% of Cravens & Co Advisors LLC’s holdings, making the stock its 16th biggest position. Cravens & Co Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,372,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Quent Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 19 shares during the period. Tidal Investments LLC increased its holdings in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after buying an additional 711 shares during the period. Plato Investment Management Ltd raised its stake in shares of Regeneron Pharmaceuticals by 1,846.3% in the 1st quarter. Plato Investment Management Ltd now owns 2,394 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 2,271 shares in the last quarter. Swedbank AB acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $129,257,000. Finally, Atria Investments Inc raised its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after buying an additional 941 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $753.03 on Wednesday. The company has a fifty day moving average price of $929.13 and a two-hundred day moving average price of $1,024.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $82.75 billion, a PE ratio of 18.63, a P/E/G ratio of 2.89 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.